Autoimmune disorders include vast and distinct illnesses
and are
characterized by an immune system-mediated attack on the body’s
own tissues. Because of their ability to impact any portion of the
body, their clinical symptoms are incredibly varied. The variations
in symptoms are normally linked with the release and activation of
vasoactive, chemotactic substances and cytokines. Cytokines perform
a multitude of vital biological tasks, such as immune response control,
inflammation, proliferation, and tissue repair. The reversal of inflammatory
cytokines and leukocyte infiltration into the inflamed tissue by natural
compounds provides an effective remedy for autoimmune diseases. Here,
the oral administration of trans-chalcone (TC) for
28 days was tested with gradually increasing doses (30, 60, and 120
mg/kg) in complete Freund’s adjuvant (CFA)-provoked joint tissue
stiffness in rats. Paw edema, arthritic index, joint stiffness, thermal
and flexion pain, C-reactive protein, and rheumatoid factor (RF) levels
were determined to check the tested drug effectiveness in a chronic
inflammatory model. Molecular docking studies revealed strong binding
affinity with inflammatory cytokines and mediators such as TNF-α,
IL-17, COX-2, and iNOS; further, they were quantified at the mRNA
level by RT-PCR and ELISA analysis. Oral administration of TC significantly
ameliorated paw edema, thymus and spleen indices, joint stiffness,
thermal and flexion pain, C-reactive protein, RF, mobility, and stance
of the treated animals. This therapeutic effectiveness was linked
with a reduction in the mRNA expression of proinflammatory cytokines
such as IL-1β, IL-6, and IL-17. The findings of the reported
research confirmed the effectiveness of TC in ameliorating joint stiffness
and flexion pain by prominently lowering the inflammatory cytokines.